The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer

Trenchant Double Swords as Predictive and Prognostic Markers

Kazuki Takada, Gouji Toyokawa, Fumihiro Shoji, Tatsuro Okamoto, Yoshihiko Maehara

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non–small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of tumor cells has emerged as a potential biomarker for predicting responses to immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 expression as a predictive and prognostic biomarker remains controversial because of the existence of various PD-L1 antibodies, scoring systems, and positivity cutoffs. In this review, we summarize the data from representative clinical trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports on the association between PD-L1 expression and clinical outcomes in patients with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and immune checkpoint factors.

Original languageEnglish
Pages (from-to)120-129
Number of pages10
JournalClinical Lung Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
Ligands
CD274 Antigen
Immunotherapy
Lung Neoplasms
Biomarkers
Molecular Targeted Therapy
Mutation
Immunologic Factors
Oncogenes
Epidermal Growth Factor Receptor
Cause of Death
Neoplasms
Radiotherapy
Clinical Trials
Drug Therapy
Survival
Antibodies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer : Trenchant Double Swords as Predictive and Prognostic Markers. / Takada, Kazuki; Toyokawa, Gouji; Shoji, Fumihiro; Okamoto, Tatsuro; Maehara, Yoshihiko.

In: Clinical Lung Cancer, Vol. 19, No. 2, 01.03.2018, p. 120-129.

Research output: Contribution to journalReview article

Takada, Kazuki ; Toyokawa, Gouji ; Shoji, Fumihiro ; Okamoto, Tatsuro ; Maehara, Yoshihiko. / The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer : Trenchant Double Swords as Predictive and Prognostic Markers. In: Clinical Lung Cancer. 2018 ; Vol. 19, No. 2. pp. 120-129.
@article{0411a4135f4141c490118d4f67cf8556,
title = "The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers",
abstract = "Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non–small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of tumor cells has emerged as a potential biomarker for predicting responses to immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 expression as a predictive and prognostic biomarker remains controversial because of the existence of various PD-L1 antibodies, scoring systems, and positivity cutoffs. In this review, we summarize the data from representative clinical trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports on the association between PD-L1 expression and clinical outcomes in patients with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and immune checkpoint factors.",
author = "Kazuki Takada and Gouji Toyokawa and Fumihiro Shoji and Tatsuro Okamoto and Yoshihiko Maehara",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.cllc.2017.10.014",
language = "English",
volume = "19",
pages = "120--129",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - The Significance of the PD-L1 Expression in Non–Small-Cell Lung Cancer

T2 - Trenchant Double Swords as Predictive and Prognostic Markers

AU - Takada, Kazuki

AU - Toyokawa, Gouji

AU - Shoji, Fumihiro

AU - Okamoto, Tatsuro

AU - Maehara, Yoshihiko

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non–small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of tumor cells has emerged as a potential biomarker for predicting responses to immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 expression as a predictive and prognostic biomarker remains controversial because of the existence of various PD-L1 antibodies, scoring systems, and positivity cutoffs. In this review, we summarize the data from representative clinical trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports on the association between PD-L1 expression and clinical outcomes in patients with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and immune checkpoint factors.

AB - Lung cancer is the leading cause of death due to cancer worldwide. Surgery, chemotherapy, and radiotherapy have been the standard treatment for lung cancer, and targeted molecular therapy has greatly improved the clinical course of patients with non–small-cell lung cancer (NSCLC) harboring driver mutations, such as in epidermal growth factor receptor and anaplastic lymphoma kinase genes. Despite advances in such therapies, the prognosis of patients with NSCLC without driver oncogene mutations remains poor. Immunotherapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has recently been shown to improve the survival in advanced NSCLC. The PD-L1 expression on the surface of tumor cells has emerged as a potential biomarker for predicting responses to immunotherapy and prognosis after surgery in NSCLC. However, the utility of PD-L1 expression as a predictive and prognostic biomarker remains controversial because of the existence of various PD-L1 antibodies, scoring systems, and positivity cutoffs. In this review, we summarize the data from representative clinical trials of PD-1/PD-L1 immune checkpoint inhibitors in NSCLC and previous reports on the association between PD-L1 expression and clinical outcomes in patients with NSCLC. Furthermore, we discuss the future perspectives of immunotherapy and immune checkpoint factors.

UR - http://www.scopus.com/inward/record.url?scp=85034437948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034437948&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2017.10.014

DO - 10.1016/j.cllc.2017.10.014

M3 - Review article

VL - 19

SP - 120

EP - 129

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 2

ER -